Clinical Case Study - 505(b)(2) Regulatory Approval, Multiple NDA-enabling Studies
Understanding Vaccines and Immunization
Your Immune System is your Body’s Defense Against Infection
You may already know that vaccines wor
RE: Testimonial: Mitra® work provided by Altasciences
PharmaVoice: Chris Perkin - Transforming the Industry With a People-Focused Approach
Chris Perkin was featured in PharmaVoice on August 1, 2019 — after being part of the PharmaVoice 100 for four consecutive years, Chris is now a RED JACKET honoree.
Re: Altasciences [Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of cannabinoids by Inhalation]
To whom it may concern,
Frequently asked SEND questions & Pro tips
|
|
Navigating the SEND requirements can be complicated. By asking the right questions upfront, you'll be able to choose a knowledgeable and experienced partner who can guide you through the process, help you avoid potential delays and prepare reliable SEND datasets for FDA submissions. Before you choose your SEND partner, read our frequently asked questions and quick pro tips. |
Altasciences’ CEO Chris Perkin Recognized as PharmaVoice Red Jacket Honoree
Laval, Québec, August 12, 2019 – Altasciences is proud to announce that CEO Chris Perkin has been recognized as a 2019 Red Jacket honoree. The Red Jacket Award was introduced by PharmaVOICE in 2014 to honor a select and distinguished group of leaders who have been lauded by their colleagues and peers numerous times as PharmaVOICE 100 designees for their many contributions to their companies and the industry at large. Chris has been a PharmaVOICE 100 designee every year since 2015, and, as a Red Jacket honoree, will be retiring the annual award for the lifetime achievement of the Red Jacket.
PharmaVOICE Red Jacket honorees:
- Challenge us to think differently, act differently, and lead differently
- Create opportunities to make what was once impossible — possible
- Are focused beyond short-term gains and are committed to executing their long-term visions in a tightly regulated and competitive industry
- Have a persistence of vision
- Are truly transforming the life sciences industry to create better health outcomes for all
- Are inspired leaders for today and tomorrow
Throughout Chris’ career, he has demonstrated a commitment to innovation, transformation, mentorship, and philanthropy. His entrepreneurial spirit and leadership have inspired Altasciences’ employees, peers, and company, and his influence is impacting the larger sphere of the life sciences industry.
“I am honored to have been selected for this recognition, which would have been impossible without the unwavering support of the Altasciences team, our sponsors, and key collaborators. I know that, working together, we can continue making positive impacts in the ever-evolving, fast-paced life sciences marketplace,” said Chris Perkin, CEO of Altasciences and Red Jacket honoree.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
CONTACT:
Julie-Ann Cabana
Altasciences
913 304-4505
jcabana@altasciences.com
BioSpace: Movers and Shakers, Aug. 9 By Alex Keown
Altasciences – Beatrice Setnik was named CSO of Quebec-based Altasciences. She has held roles with Ventana Clinical Research in Canada, King Pharmaceuticals and Pfizer in North Carolina, and since 2014 with Syneos Health (formerly INC Research).